Articles
30.11.2022
Reflecting on the Pricing & Market Access tre...

Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...

Read more
Articles
25.10.2022
How is International Reference Pricing used within...

We discuss the advantages and disadvantages of using international reference pricing for consistent ...

Read more
Articles
18.10.2022
What are the pricing considerations when launching...

We explore the pricing dynamics of biosimilars, which depend on the type of biosimilar, its indicati...

Read more
Articles
12.10.2022
How important is HTA when launching a biosimilar i...

The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...

Read more
Articles
21.09.2022
Pricing and reimbursement of cell and gene therapi...

Introduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...

Read more
Articles
21.09.2022
Are payers willing to pay for innovation for gene ...

Introduction Gene and CAR-T cell therapies are often heralded as the future of healthcare, where gro...

Read more
Articles
24.08.2022
Correlating value with price in the US oncology ma...

Introduction Despite the impact of the COVID-19 pandemic with many resources steered towards managem...

Read more
Articles
24.08.2022
How do you win the race to market? Our top conside...

Introduction Early Access Programs, also known as special access programs, give patients access to m...

Read more
Articles
24.08.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
Articles
24.08.2022
What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.